|
|
|
|
| LEADER |
00000cam a22000002c 4500 |
| 001 |
1093449950 |
| 003 |
DE-627 |
| 005 |
20220610111407.0 |
| 007 |
tu |
| 008 |
910305s1977 xx ||||| 00| ||eng c |
| 035 |
|
|
|a (DE-627)1093449950
|
| 035 |
|
|
|a (DE-576)023449950
|
| 035 |
|
|
|a (DE-599)BSZ023449950
|
| 035 |
|
|
|a (OCoLC)03168627
|
| 035 |
|
|
|a (DE-604)8092339131
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 082 |
0 |
|
|a 362.2/93/097471
|
| 084 |
|
|
|a XI 5800
|2 rvk
|0 (DE-625)rvk/153018:12905
|
| 100 |
1 |
|
|a Newman, Robert G.
|4 aut
|
| 245 |
1 |
0 |
|a Methadone treatment in narcotic addiction
|b program management, findings, and prospects for the future
|c Robert G. Newman
|
| 264 |
|
1 |
|a New York [u.a.]
|b Academic Pr.
|c 1977
|
| 300 |
|
|
|a XXI, 285 S.
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 583 |
1 |
|
|a Archivierung prüfen
|c 20200919
|f DE-640
|z 2
|2 pdager
|
| 936 |
r |
v |
|a XI 5800
|b Allgemeines
|k Medizin
|k Pharmakologie und Toxikologie
|k Spezielle Pharmakologie und Toxikologie
|k Nervensystem und Sinnesorgane (Neuropharmakologie)
|k Psychopharmaka, Rauschgifte
|k Allgemeines
|0 (DE-627)127150622X
|0 (DE-625)rvk/153018:12905
|0 (DE-576)20150622X
|
| 951 |
|
|
|a BO
|
| ELC |
|
|
|b 1
|
| LOK |
|
|
|0 000 xxxxxcx a22 zn 4500
|
| LOK |
|
|
|0 001 2160485659
|
| LOK |
|
|
|0 003 DE-627
|
| LOK |
|
|
|0 004 1093449950
|
| LOK |
|
|
|0 005 20020606000000
|
| LOK |
|
|
|0 008 910305||||||||||||||||ger|||||||
|
| LOK |
|
|
|0 040
|a DE-21
|c DE-627
|d DE-21
|
| LOK |
|
|
|0 852
|a DE-21
|
| LOK |
|
|
|0 852 1
|c KB 9 A 987
|9 00
|
| LOK |
|
|
|0 935
|a krim
|
| LOK |
|
|
|0 936ln
|a k9.7.6
|
| ORI |
|
|
|a SA-MARC-krimdoka001.raw
|
| SIG |
|
|
|a UB: KB 9 A 987
|
